Phase 3 results show that daclizumab reduces disease activity in relapsing-remitting multiple sclerosis by half compared with interferon, as measured by brain imaging, with skin and other side effects. The drug works in surprising ways that are revealing new details about the pathogenesis of MS.
Carol Cruzan Morton
Three might be the lucky number for daclizumab, an investigational drug for relapsing-remitting multiple sclerosis with...
Clinical Research, Drug Development, Laboratory Research, Meetings
Depression may be the leading cause of disability and death among people with MS. Importantly, it's one of the few MS symptoms that can—and should— be completely reversed through treatment, says Adam Kaplin MD PhD.
This population-based study of more than 28,000 Swedish citizens with multiple sclerosis found strikingly lower ratios of familial recurrence of the disease compared with most previous studies
Steven Fox
A new population-based study of people with multiple sclerosis has found what the authors term...